Innovative Rotavirus Vaccine Using Chimeric Particles

Health & Safety

Problem Solved

Rotavirus is a leading cause of severe diarrhea in children worldwide, often resulting in hospitalization and even death. Traditional vaccines can be costly, have limited efficacy, and may not provide broad protection against diverse rotavirus strains.

Core Features

This invention introduces a chimeric virus-like particle (cVLP) vaccine that combines a hepatitis B core protein with a rotavirus VP8* protein. This combination acts as both an adjuvant and an antigen, enhancing the immune response. The vaccine is produced using a prokaryotic expression system, specifically Escherichia coli, making it potentially more cost-effective and easier to produce.

Inventive Step

The novel aspect of this invention lies in the integration of the VP8* domain into the major immunodominant region of the hepatitis B core protein, creating a chimeric structure that effectively induces VP8*-specific antibodies. This approach is unique as it leverages the structural properties of virus-like particles to enhance immunogenicity without using live viruses.

Benefits

The vaccine is designed to induce neutralizing antibodies, IgA, and IgG specific to the rotavirus VP8* domain, potentially offering broader and more effective protection against rotavirus infections. Its production in E. coli could lower manufacturing costs and increase accessibility, especially in low-resource settings.

Broader Impact

This invention could significantly reduce the global burden of rotavirus-related illnesses, particularly in developing countries. By improving vaccine accessibility and efficacy, it contributes to better public health outcomes and reduces healthcare costs associated with treating rotavirus infections.

Disclaimer

The image and video are AI-generated based on the description of the invention in its patent application and are intended for illustrative purposes only.

It explains the concept and is not the actual product as it still needs to be developed.

Market Need

Rotavirus is a major cause of severe diarrhea in children, with significant morbidity and mortality rates worldwide. Current vaccines have limitations in terms of cost, efficacy, and strain coverage. There is a pressing need for more effective and affordable solutions.

Technical Feasibility

The use of chimeric virus-like particles and prokaryotic expression systems is a well-established method in vaccine development, suggesting high technical feasibility. The integration of the VP8* domain into the hepatitis B core protein is an innovative approach that enhances immunogenicity.

Potential Applications

The primary application is in the prevention of rotavirus infections in children. The vaccine could be particularly beneficial in developing countries where the disease burden is highest and healthcare resources are limited.

Uniqueness

This invention stands out due to its novel chimeric structure and cost-effective production method. By targeting the VP8* domain, it aims to provide broader protection against diverse rotavirus strains.

Market Size

The global rotavirus vaccine market was valued at approximately $7 billion in 2020 and is expected to grow as demand for effective vaccines increases.

Commercial Viability

Given the significant market need, technical feasibility, and potential for cost-effective production, this invention has strong commercial viability. It addresses a critical public health issue and could capture a substantial share of the vaccine market.